2/27
07:03 pm
vrdn
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]
Low
Report
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]
2/27
01:33 pm
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.
2/26
07:11 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
07:01 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
2/5
02:57 pm
vrdn
Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
Low
Report
Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
2/4
08:03 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
2/3
08:50 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
1/26
02:08 pm
vrdn
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
Low
Report
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
1/23
05:09 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
10:06 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
1/9
06:10 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
12:49 pm
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
1/7
10:02 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
07:22 am
vrdn
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
Low
Report
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
1/6
07:01 am
vrdn
Viridian Therapeutics Prepares for Transformational 2026
Low
Report
Viridian Therapeutics Prepares for Transformational 2026
12/23
08:02 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Needham & Company LLC from $34.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Needham & Company LLC from $34.00 to $42.00. They now have a "buy" rating on the stock.
12/22
07:15 am
vrdn
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]
Low
Report
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]
12/22
07:00 am
vrdn
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Low
Report
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
12/10
08:36 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
12/5
07:00 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)